国际肿瘤学杂志››2024,Vol. 51››Issue (2): 95-98.doi:10.3760/cma.j.cn371439-20231008-00013
马正红1, 姜超2(
)
收稿日期:2023-10-08修回日期:2023-11-04出版日期:2024-02-08发布日期:2024-04-03通讯作者:姜超，Email：
Ma Zhenghong1, Jiang Chao2()
Received:2023-10-08Revised:2023-11-04Online:2024-02-08Published:2024-04-03Contact:Jiang Chao，Email：
摘要：
随着KRASG12C突变在非小细胞肺癌靶向治疗中作用机制的不断深入研究，KRASG12C由“不可成药”发展为重要的靶向治疗位点。KRASG12C突变抑制剂在非小细胞肺癌靶向治疗中实现了有效率和生存的双进展。尽管治疗产生的耐药不可避免，但通过其耐药机制的研究发现，联合用药是克服或减少耐药的途径之一。
马正红, 姜超. 非小细胞肺癌KRASG12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
Ma Zhenghong, Jiang Chao. Progress of KRASG12Cmutations in non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(2): 95-98.
| [1] | Liu P, Wang Y, Xin L. Targeting the untargetable KRAS in cancer therapy[J].Acta Pharm Sin B,2019,9(5): 871-879. DOI:10.1016/j.apsb.2019.03.002. pmid:31649840 |
| [2] | Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer[J].Cancer Metastasis Rev,2020,39(4): 1029-1038. DOI:10.1007/s10555-020-09915-5. |
| [3] | Judd J, Abdel Karim N, Khan H, et al. Characterization of KRAS mutation subtypes in non-small cell lung cancer[J].Mol Cancer Ther,2021,20(12): 2577-2584. DOI:10.1158/1535-7163.MCT-21-0201. pmid:34518295 |
| [4] | Ricciuti B, Alessi JV, Elkrief A, et al. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer[J].Ann Oncol,2022,33(10): 1029-1040. DOI:10.1016/j.annonc.2022.07.005. pmid:35872166 |
| [5] | Negrao MV, Araujo HA, Lamberti G, et al. Comutations and KRASG12Cinhibitor efficacy in advanced NSCLC[J].Cancer Discov,2023,13(7): 1556-1571. DOI:10.1158/2159-8290.CD-22-1420. |
| [6] | Sebastian M, Eberhardt WEE, Hoffknecht P, et al. KRASG12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)[J].Lung Cancer,2021,154: 51-61. DOI:10.1016/j.lungcan.2021.02.005. pmid:33611226 |
| [7] | Cui W, Franchini F, Alexander M, et al. Real world outcomes in KRASG12Cmutation positive non-small cell lung cancer[J].Lung Cancer,2020,146: 310-317. DOI:10.1016/j.lungcan.2020.06.030. |
| [8] | Wu MY, Zhang EW, Strickland MR, et al. Clinical and imaging features of non-small cell lung cancer with G12C KRAS mutation[J].Cancers (Basel),2021,13(14): 3572. DOI:10.3390/cancers13143572. |
| [9] | Reck M, Carbone DP, Garassino M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches[J].Ann Oncol,2021,32(9): 1101-1110. DOI:10.1016/j.annonc.2021.06.001. pmid:34089836 |
| [10] | Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRASG12Csomatic mutations across race, sex, and cancer type[J].N Engl J Med,2021,384(2): 185-187. DOI:10.1056/NEJMc2030638. |
| [11] | Ou SI, Jänne PA, Leal TA, et al. First-in-human phase Ⅰ/ⅠB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12Csolid tumors (KRYSTAL-1)[J].J Clin Oncol,2022,40(23): 2530-2538. DOI:10.1200/JCO.21.02752. |
| [12] | Arbour KC, Rizvi H, Plodkowski AJ, et al. Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer[J].Clin Cancer Res,2021,27(8): 2209-2215. DOI:10.1158/1078-0432.CCR-20-4023. pmid:33558425 |
| [13] | Hong DS, Fakih MG, Strickler JH, et al. KRASG12Cinhibition with sotorasib in advanced solid tumors[J].N Engl J Med,2020,383(13): 1207-1217. DOI:10.1056/NEJMoa1917239. |
| [14] | Ferdinandos S, Bob TL, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation[J].N Engl J Med,2021,384(25): 2371-2381. DOI:10.1056/NEJMoa2103695. |
| [15] | Xue JY, Zhao Y, Aronowitz J, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition[J].Nature,2020,577(7790): 421-425. DOI:10.1038/s41586-019-1884-x. |
| [16] | Koster KL, Appenzeller C, Lauber A, et al. Sotorasib shows intracranial activity in patients with KRASG12C-mutated adenocarcinoma of the lung and untreated active brain metastases[J].Case Rep Oncol,2022,15(2): 720-725. DOI:10.1159/000525341. |
| [17] | Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions[J].Nature,2013,503(7477): 548-551. DOI:10.1038/nature12796. |
| [18] | O'Bryan JP. Pharmacological targeting of RAS: recent success with direct inhibitors[J].Pharmacol Res,2019,139: 503-511. DOI:10.1016/j.phrs.2018.10.021. pmid:30366101 |
| [19] | Hallin J, Engstrom LD, Hargis L, et al. The KRASG12Cinhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients[J].Cancer Discov,2020,10(1): 54-71. DOI:10.1158/2159-8290.CD-19-1167. pmid:31658955 |
| [20] | Grace KD, Ramaswamy G, Vamsidhar V, et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100[J].J Clin Oncol,2023,41(18): 3311-3317. DOI:10.1200/JCO.22.02524. |
| [21] | Brazel D, Kim J, Ou SI. CodeBreaK 200: sotorasib (AMG510) has broken the KRAS G12C+NSCLC enigma code[J].Lung Cancer (Auckl),2023,14: 31-39. DOI:10.2147/LCTT.S403614. |
| [22] | Isaksson J, Berglund A, Louie K, et al. KRASG12Cmutant non-small cell lung cancer linked to female sex and high risk of CNS metastasis: population-based demographics and survival data from the National Swedish Lung Cancer Registry[J].Clin Lung Cancer,2023,24(6): 507-518. DOI:10.1016/j.cllc.2023.05.002. pmid:37296038 |
| [23] | Sabari JK, Velcheti V, Shimizu K, et al. Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer[J].Clin Cancer Res,2022,28(15): 3318-3328. DOI:10.1158/1078-0432.CCR-22-0383. pmid:35404402 |
| [24] | Negrao MV, Spira AI, Heist RS, et al. Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRASG12C-mutated non-small-cell lung cancer who have untreated CNS metastases[J].J Clin Oncol,2023,41(28): 4472-4477. DOI:10.1200/JCO.23.00046. |
| [25] | Zhang J, Johnson M, Barve M, et al. Practical guidance for the management of adverse events in patients with KRASG12C-mutated non-small cell lung cancer receiving adagrasib[J].Oncologist,2023,28(4): 287-296. DOI:10.1093/oncolo/oyad051. pmid:36892150 |
| [26] | Bekaii-Saab TS, Yaeger R, Spira AI, et al. Adagrasib in advanced solid tumors harboring a KRASG12Cmutation[J].J Clin Oncol,2023,41(25): 4097-4106. DOI:10.1200/JCO.23.00434. |
| [27] | Zhao Y, Murciano-Goroff YR, Xue JY, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition[J].Nature,2021,599(7886): 679-683. DOI:10.1038/s41586-021-04065-2. |
| [28] | Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity[J].Nature,2019,575(7781): 217-223. DOI:10.1038/s41586-019-1694-1. |
| [29] | Pantsar T. KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations[J].Sci Rep,2020,10(1): 11992. DOI:10.1038/s41598-020-68950-y. |
| [30] | Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRASG12Cinhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments[J].J Thorac Oncol,2021,16(8): 1321-1332. DOI:10.1016/j.jtho.2021.04.015. |
| [31] | Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival[J].Cancer Cell,2021,39(3): 441-442. DOI:10.1016/j.ccell.2021.02.009. |
| [32] | Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRASG12Cinhibition in cancer[J].N Engl J Med,2021,384(25): 2382-2393. DOI:10.1056/NEJMoa2105281. |
| [33] | Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRASG12Cinhibition in colorectal cancer[J].Cancer Discov,2020,10(8): 1129-1139. DOI:10.1158/2159-8290.CD-20-0187. pmid:32430388 |
| [34] | Yaeger R, Mezzadra R, Sinopoli J, et al. Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer[J].Cancer Discov,2023,13(1): 41-55. DOI:10.1158/2159-8290.CD-22-0405. |
| [35] | Zhang SS, Nagasaka M. Spotlight on sotorasib (AMG 510) for KRASG12Cpositive non-small cell lung cancer[J].Lung Cancer (Auckl),2021,12: 115-122. DOI:10.2147/LCTT.S334623. |
| [36] | Christofyllakis K, Monteiro AR, Cetin O, et al. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: a young International Society of Geriatric Oncology report[J].J Geriatr Oncol,2022,13(8): 1071-1083. DOI:10.1016/j.jgo.2022.04.013. pmid:35525790 |
| [37] | Brown WS, McDonald PC, Nemirovsky O, et al. Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1/2 complexes in pancreatic cancer[J].Cell Rep Med,2020,1(8): 100131. DOI:10.1016/j.xcrm.2020.100131. |
| [38] | Hamarsheh S, Groß O, Brummer T, et al. Immune modulatory effects of oncogenic KRAS in cancer[J].Nat Commun,2020,11(1): 5439. DOI:10.1038/s41467-020-19288-6. pmid:33116132 |
| [1] | 钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331. |
| [2] | 郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353. |
| [3] | 王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369. |
| [4] | 王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384. |
| [5] | 范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266. |
| [6] | 王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285. |
| [7] | 顾芳萌, 徐晨阳, 雷大鹏.人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307. |
| [8] | 王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟.铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311. |
| [9] | 张文馨, 夏泠, 彭晋, 周福祥.甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315. |
| [10] | 王昆, 周中新, 臧其威.血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203. |
| [11] | 杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇.信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216. |
| [12] | 姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222. |
| [13] | 胡婷婷, 王越华.电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226. |
| [14] | 杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238. |
| [15] | 张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
